| [1] |
Vidaurri⁃de la Cruz H, Tamayo⁃Sánchez L, Durán⁃McKinster C, et al. Phakomatosis pigmentovascularis ⅡA and ⅡB: clinical findings in 24 patients[J]. J Dermatol, 2003,30(5):381⁃388. DOI: 10.1111/j.1346⁃8138.2003.tb00403.x.
|
| [2] |
Fernández⁃Guarino M, Boixeda P, de Las Heras E, et al. Phakomatosis pigmentovascularis: clinical findings in 15 patients and review of the literature[J]. J Am Acad Dermatol, 2008,58(1):88⁃93. DOI: 10.1016/j.jaad.2007.08.012.
|
| [3] |
Dutta A, Ghosh SK, Bandyopadhyay D, et al. Phakomatosis pigmentovascularis: a clinical profile of 11 Indian patients[J]. Indian J Dermatol, 2019,64(3):217⁃223. DOI: 10.4103/ijd.IJD_385_18.
|
| [4] |
Shin H, Kim YG, Kim YE, et al. Clinical characteristics and treatment of 52 cases of phakomatosis pigmentovascularis[J]. J Dermatol, 2019,46(10):843⁃848. DOI: 10.1111/1346⁃8138.15035.
|
| [5] |
Kumar A, Zastrow DB, Kravets EJ, et al. Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: case series and literature review[J]. Am J Med Genet A, 2019,179(6):966⁃977. DOI: 10.1002/ajmg.a.61134.
|
| [6] |
黄士通, 杨扬帆, 余敏斌. 色素血管性斑痣性错构瘤及其研究进展[J]. 国际眼科纵览, 2021,45(4):300⁃306. DOI: 10.3760/cma.j.issn.1673⁃5803.2021.04.006.
|
| [7] |
Happle R. Phacomatosis pigmentovascularis revisited and reclassified[J]. Arch Dermatol, 2005,141(3):385⁃388. DOI: 10.1001/archderm.141.3.385.
|
| [8] |
Torchia D. Phacomatosis melanorosea, unearthed[J]. Eur J Dermatol, 2012,22(4):582⁃583. DOI: 10.1684/ejd.2012.1749.
|
| [9] |
Fry MV, Williams BK, Kim HJ, et al. Choroidal melanoma in phakomatosis pigmentovascularis with overlapping sturge⁃weber syndrome and Klippel⁃Trenaunay syndrome[J]. Retin Cases Brief Rep, 2023,17(2):130⁃133. DOI: 10.1097/ICB.000000000 0001154.
|
| [10] |
Sen S, Bala S, Halder C, et al. Phakomatosis pigmentovascularis presenting with Sturge⁃Weber syndrome and Klippel⁃Trenaunay syndrome[J]. Indian J Dermatol, 2015,60(1):77⁃79. DOI: 10. 4103/0019⁃5154.147801.
|
| [11] |
Zhang B, Ma L. Updated classification and therapy of vascular malformations in pediatric patients[J]. Pediatr Investig, 2018,2(2):119⁃123. DOI: 10.1002/ped4.12043.
|
| [12] |
Thomas AC, Zeng Z, Rivière JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis[J]. J Invest Dermatol, 2016,136(4):770⁃778. DOI: 10.1016/j.jid.2015. 11.027.
|
| [13] |
Jordan M, Carmignac V, Sorlin A, et al. Reverse phenotyping in patients with skin capillary malformations and mosaic GNAQ or GNA11 mutations defines a clinical spectrum with genotype⁃phenotype correlation[J]. J Invest Dermatol, 2020,140(5):1106⁃1110. DOI: 10.1016/j.jid.2019.08.455.
|
| [14] |
余文林, 李勤, 曾东, 等. 色素血管性斑痣性错构瘤病23例临床分析[J]. 中国美容医学, 2009,18(5):679⁃681. DOI: 10. 3969/j.issn.1008⁃6455.2009.05.032.
|
| [15] |
黄玉成, 李雪莉, 李天举, 等. 色素血管性斑痣性错构瘤病15例临床分析[J]. 中国皮肤性病学杂志, 2012,26(4):315⁃316.
|
| [16] |
Huang Y, Yang J, Bi M, et al. Photodynamic therapy for the treatment of port⁃wine stains in phakomatosis pigmentovascularis[J]. J Cosmet Dermatol, 2024,23(9):2888⁃2894. DOI: 10.1111/jocd.16351.
|
| [17] |
Sánchez⁃Espino LF, Ivars M, Antoñanzas J, et al. Sturge⁃Weber syndrome: a review of pathophysiology, genetics, clinical features, and current management approache[J]. Appl Clin Genet, 2023,16:63⁃81. DOI: 10.2147/TACG.S363685.
|
| [18] |
Pilch J, Mizera J, Tota M, et al. GNAQ/GNA11⁃related benign and malignant entities⁃a common histoembriologic origin or a tissue⁃dependent coincidence[J]. Cancers (Basel), 2024,16(21):3672. DOI: 10.3390/cancers16213672.
|
| [19] |
Rujimethapass N, Manuskiatti W, Wanitphakdeedecha R, et al. Ocular manifestations of facial port⁃wine stain, nevus of Ota, and phakomatosis pigmentovascularis in Asian patients[J]. J Am Acad Dermatol, 2021,85(5):1194⁃1200. DOI: 10.1016/j.jaad. 2020.04.169.
|